BPC-157 is in the Federal Register. That is new. The evidence base is not.

On October 28, 2026, HHS issued an enforcement discretion policy creating a conditional pharmacy pathway for six peptides, including BPC-157 acetate. This is a regulatory development. It is not a clinical one.

What "Enforcement Discretion" Means for the Evidence

The policy is non-binding and can be revoked.

It does not establish that BPC-157 is safe. It does not establish that BPC-157 is effective. It means HHS has said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians that compound it under specific conditions. Those are different things.

The Human Evidence

The entire published human evidence base for BPC-157 is 30 participants across three studies. A PROSPERO-registered systematic review published October 8, 2026 in Acta Orthopaedica Belgica searched Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov through June 1, 2026 and found exactly three qualifying human studies. The overall certainty of evidence was graded "very low" using the GRADE framework — the floor of the scale — due to serious risk of bias, indirectness, and imprecision. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials.

Separately, a clinical-note analysis of more than 1,500 patient records found 1,039 with documented BPC-157 use between 2020 and early 2026 — newly confirmed users rising from 4 per quarter in 2020 to 134 per quarter in early 2026 (a roughly 33-fold increase). Of the 205 users with a documented source, 35% named a gray-market peptide vendor and 36% a compounding pharmacy. This is an EHR observational preprint, not a clinical trial — it documents disclosure, not outcomes or causation. It has not been peer-reviewed.

Source (systematic review): Poolton JT, Minett J, Kazmi A. "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety." Acta Orthopaedica Belgica, published online October 8, 2026. DOI 10.52628/92.3.15837. actaorthopaedica.be

Source (EHR preprint): Venkatakrishnan AJ, Marwaha A, Gregg CJ, et al. "Rising use of unapproved BPC-157 ('Wolverine peptide') and associated patient-reported outcomes curated from clinical notes." Preprints.org, September 7, 2026. DOI 10.20944/preprints202609.0501.v1. Preprint — not peer-reviewed. Covered by AJMC, October 29, 2026. ajmc.com

The Research Concentration Problem

An investigation published by Undark on May 29, 2026 — "A Peptide, a Secretive Scientist, and a Debate Over Evidence" by Sara Talpos — documents the history of BPC-157 and the scientific concerns around it. Based on extensive interviews with Sikiric, his collaborators, and outside experts in drug development and peptide research, the piece establishes that:

In 1975, as a medical student in what was then Yugoslavia, Predrag Sikiric had the idea that led to the BPC-157 project. The gastric-juice work began in the 1980s, and the peptide was identified in 1989. He and his longtime collaborator Sven Seiwerth estimate that 100 or more current and former PhD students have worked on the project.
As one unnamed physician quoted in the Undark article put it, BPC-157 "should not be used by humans" until proper human studies are conducted.
PLIVA, a Zagreb pharmaceutical company, ran two early-stage trials of BPC-157 for ulcerative colitis in the early 2000s. The full results were never published.

Undark also notes that while most BPC-157 evidence comes from Sikiric's Zagreb lab, teams in Taiwan, South Korea, China, and Turkey have published positive studies. However, chemist Anna Mapp is quoted saying the full protein sequence was never published — meaning the original work cannot be reproduced. That is the core concern: not fabrication, but an absence of the published sequence that would allow independent verification.

The Atlantic profiled the broader peptide wellness culture in its December 2026 issue ("Is There Anything BPC-157 Can't Cure?" by Tom Bartlett, published online October 27, 2026), covering the range of claims made for BPC-157 and the conference culture around peptide promotion. That article is paywalled past its opening section and no specific claims from the paywalled portion are quoted here.

The Animal Literature

BPC-157 has a substantial animal literature. Rodent studies have shown effects on wound healing, tendon repair, and gut motility. Animal findings are not transferable to humans without human trials — which, as noted above, are almost entirely absent.

What FDA's Own Scientists Said

According to the Associated Press, FDA scientific staff opposed the HHS policy and had little input on it, warning it could undermine the agency's mission of keeping unsafe products off the market, according to six people familiar with the policy. The committee that voted in July 2026 voted 8-6 to recommend BPC-157 for the 503A Bulks List, over FDA staff objections. Advisory committee votes are non-binding. The enforcement discretion policy preceded formal rulemaking and does not reflect FDA's scientific position.

What the Gray Market Provides

Of the 205 BPC-157 users in the EHR preprint with a documented source, 35% named a gray-market peptide vendor and 36% a compounding pharmacy. Gray-market supply chains operate without the manufacturing and testing requirements that apply to licensed compounding pharmacies.

What the Pharmacy Pathway Requires

Under the HHS enforcement discretion policy, a licensed 503A pharmacy compounding BPC-157 acetate must:

Dispense only single-peptide products (no combination products)
Use API from an FDA-registered CGMP original manufacturer
Provide a certificate of analysis for identity, purity, potency, and contaminants
Dispense only on a patient-specific prescription
Limit dosage forms to those specified per peptide (BPC-157 acetate: subcutaneous, intramuscular, oral, or topical)
Report adverse events via MedWatch
Label every product as not for resale.

These are documented manufacturing and testing requirements that gray-market products do not carry. They are not the same as FDA approval.

The Honest Summary

BPC-157 has a substantial animal literature, an almost nonexistent human evidence base, an origin sequence that was never fully published (Undark), and a new conditional pharmacy pathway with documented manufacturing and testing requirements — without creating new evidence.

Anyone building a clinical or personal protocol around BPC-157 is working from very limited human data. That may change if well-designed human trials follow the new pathway. It has not changed yet.

This post contains no compound or dose recommendations. Nothing here is medical advice.

Sources:

Poolton JT, Minett J, Kazmi A. "Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety." Acta Orthopaedica Belgica, published October 8, 2026. DOI 10.52628/92.3.15837. actaorthopaedica.be
Venkatakrishnan AJ, Marwaha A, Gregg CJ, et al. "Rising use of unapproved BPC-157 ('Wolverine peptide') and associated patient-reported outcomes curated from clinical notes." Preprints.org, September 7, 2026. DOI 10.20944/preprints202609.0501.v1. Preprint — not peer-reviewed. Covered by AJMC, October 29, 2026. ajmc.com
Talpos S. "A Peptide, a Secretive Scientist, and a Debate Over Evidence." Undark, May 29, 2026. undark.org
Bartlett T. "Is There Anything BPC-157 Can't Cure?" The Atlantic, December 2026 issue, published online October 27, 2026. theatlantic.com
Perrone M. "RFK Jr. eases access to unproven peptides despite opposition from FDA scientists." Associated Press, October 28, 2026. apnews.com
Federal Register Doc. 2026-22192, published October 30, 2026. Docket HHS-OASH-2026-0496.

BPC-157: What the Evidence Actually Shows in 2026